Birgit Knoechel
No Rating Available
(Learn About Our Rating System)

Birgit Knoechel, MD, PhD

Languages spoken: English

Clinical Locations

Primary Location

Primary Children's Hospital

Bone Marrow Transplant
100 N Mario Capecchi Drive
Salt Lake City , UT 84113
801-662-4700
Get Directions

Dr. Knoechel is a physician-scientist and Associate Professor of Pediatrics at the University of Utah School of Medicine in the Division of Pediatric Hematology/Oncology. She is a member of the division of pediatric hematology/oncology at the University of Utah and Primary Children’s Hospital.

Dr. Knoechel received her M.D. and Ph.D. degree from Albert-Ludwigs-University in Freiburg, Germany, completed her pediatric residency at UCSF and a fellowship in Pediatric Hematology/Oncology/Stem Cell Transplantation at Dana-Farber Cancer Institute and Boston Children’s Hospital, where she was chief fellow. She then joined the faculty as attending physician and independent investigator at Dana-Farber / Boston Children’s Cancer and Blood Disorder Center and Assistant Professor of Pediatrics at Harvard Medical School.

Dr. Knoechel is board-certified in Pediatrics and Pediatric Hematology / Oncology. Her clinical expertise is in the treatment of children, adolescents, and young adults with hematologic malignancies such as leukemia and lymphoma, stem cell transplantation and immunotherapies.

Dr. Knoechel is an independent investigator at Huntsman Cancer Institute, where her lab focuses on investigating epigenetic dependencies and their implications for cancer cell plasticity and the immune microenvironment in lymphoid malignancies with the goal to design the next generation of immunotherapies. She is a member of the American Society of Hematology, American Association for Cancer Research, Society for Pediatric Research, American Society of Pediatric Hematology/Oncology, American Society for Transplantation and Cellular Therapy and the Children’s Oncology Group.

Specialties

Board Certification

Educational Commission for Foreign Medical Graduates
American Board of Pediatrics (Pediatrics)
American Board of Pediatrics (Sub: Pediatric Hematology-Oncology)

Dr. Knoechel is a physician-scientist and Associate Professor of Pediatrics at the University of Utah School of Medicine in the Division of Pediatric Hematology/Oncology. She is a member of the division of pediatric hematology/oncology at the University of Utah and Primary Children’s Hospital.

Dr. Knoechel received her M.D. and Ph.D. degree from Albert-Ludwigs-University in Freiburg, Germany, completed her pediatric residency at UCSF and a fellowship in Pediatric Hematology/Oncology/Stem Cell Transplantation at Dana-Farber Cancer Institute and Boston Children’s Hospital, where she was chief fellow. She then joined the faculty as attending physician and independent investigator at Dana-Farber / Boston Children’s Cancer and Blood Disorder Center and Assistant Professor of Pediatrics at Harvard Medical School.

Dr. Knoechel is board-certified in Pediatrics and Pediatric Hematology / Oncology. Her clinical expertise is in the treatment of children, adolescents, and young adults with hematologic malignancies such as leukemia and lymphoma, stem cell transplantation and immunotherapies.

Dr. Knoechel is an independent investigator at Huntsman Cancer Institute, where her lab focuses on investigating epigenetic dependencies and their implications for cancer cell plasticity and the immune microenvironment in lymphoid malignancies with the goal to design the next generation of immunotherapies. She is a member of the American Society of Hematology, American Association for Cancer Research, Society for Pediatric Research, American Society of Pediatric Hematology/Oncology, American Society for Transplantation and Cellular Therapy and the Children’s Oncology Group.

Board Certification and Academic Information

Academic Departments Internal Medicine -Adjunct Associate Professor
Pediatrics -Associate Professor
Academic Divisions Hematology & Hematologic Malignancies
Board Certification
Educational Commission for Foreign Medical Graduates
American Board of Pediatrics (Pediatrics)
American Board of Pediatrics (Sub: Pediatric Hematology-Oncology)

Education history

Professional Medical Medicine - University of Hamburg Physikum
Professional Medical Medicine - Albert Ludwig University of Freiburg M.D.
Graduate Training Immunology - Albert Ludwig University of Freiburg Ph.D.
Residency Internal Medicine: Hematology/Oncology - University Medical Center, Albert Ludwig University Resident
Residency Pediatrics - University Medical Center, Carl Gustav Carus University Medical School Resident
Residency Pediatric Hematology/Oncology - University Medical Center, Medical School Resident
Graduate Training Immunology - University of California, San Francisco Postdoctoral Scholar
Residency Pediatrics - University of California, San Francisco Resident
Fellowship Pediatric Hematology/Oncology - Dana-Farber Cancer Institute, Boston Children¿s Hospital Clinical Fellow
Fellowship Cancer Epigenetics - Massachusetts General Hospital, Broad Institute of MIT and Harvard Research Fellow
Fellowship Pediatric Hematology/Oncology - Dana-Farber Cancer Institute, Boston Children¿s Hospital Chief Fellow

Selected Publications

Journal Article

  1. Li S, Li J, Faruque HA, Shami P, Knoechel B, Lohr J, Sborov D, Yang J, Kope'ek (2025). Self-Assembling Multi-Antigen T Cell Hybridizers for Precision Immunotherapy of Multiple Myeloma. Advanced healthcare materials, 14(29), e02156.
  2. Heavican-Foral TB, Korell F, Scarfò I, Wiggers CRM, B AT, Eisenbies Z, Powers F, Hegel J, Liu J, Kulp S, Silva H, Wu G, Letai A, Stegmaier K, Lohr JG, Weinstock DM, Maus MV, Knoechel (2025). Combining MCL-1 inhibition and CD37-directed chimeric antigen receptor T cells as an effective strategy to target T-cell lymphoma. Leukemia, 39(10), 2452-2464.
  3. Wiggers CRM, Yüzügüldü B, Tadros NG, Heavican-Foral TB, Cho EY, Eisenbies ZC, Ozdemir M, Kulp SB, Chae YC, Gutierrez A, Lohr JG, Knoechel (2025). Genome-wide CRISPR screen identifies IRF1 and TFAP4 as transcriptional regulators of Galectin-9 in T cell acute lymphoblastic leukemia. Science advances, 11(12), eads8351.
  4. Waldschmidt JM, Sotudeh N, Arora S, Vijaykumar T, Anand P, Stuart H, Frede J, Campbell T, Kaiser SM, Zheng X, Munshi NC, Anderson KC, Einsele H, Yee AJ, Knoechel B, Lohr JG, Raje N (2025). Nivolumab to restore T-cell fitness in CAR-T refractory multiple myeloma. Blood advances, 9(5), 1132-1136.
  5. Frede J, Poller JC, Shi K, Stuart H, Sotudeh N, Havig C, Lim K, Wiggers CRM, Cho EY, Vijaykumar T, Liu J, Waldschmidt JM, Nair MS, Anand P, Dimitrova V, Montanaro A, Yee AJ, Munshi NC, Anderson KC, Martin N, Kaiser SM, Raab MS, Raje NS, Knoechel B, Lohr J (2025). The endogenous T cell landscape is reshaped by CAR-T cell therapy and predicts treatment response in multiple myeloma. Leukemia, 39(12), 3004-3014.
  6. Wiggers CRM, Cho EY, Ozdemir M, Bamgbose G, Hegel J, Frede J, Warlitz F, Heavican-Foral TB, Pop I, Shraim R, Pölönen P, Koch V, Tran TH, Mullighan CG, Teachey DT, Bledsoe JR, Pikman Y, Harris MH, Place AE, Silverman LB, Lohr JG, Knoechel (2025). Remodeling of the immune microenvironment is linked to adverse outcome in pediatric T cell acute lymphoblastic leukemia. Nature communications, 16(1), 10263.
  7. Blocka J, Lim K, Stuart H, Frede J, Tadros NG, Wiggers CRM, Hanna GJ, Knoechel B, Lohr J (2025). Cell-free DNA as a complementary marker of therapeutic futility in adenoid cystic carcinoma. Oral oncology, 169, 107688.
  8. Hernandez-Lopez P, Vijaykumar T, Anand P, Auclair D, Frede J, Knoechel B, Lohr JG (2024). Dual role of signaling pathways in myeloma requires cell-type specific targeting of ligand-receptor interactions. Blood Adv, 8(12), 3173-3185.
  9. Li L, Mohanty V, Dou J, Huang Y, Banerjee PP, Miao Q, Lohr JG, Vijaykumar T, Frede J, Knoechel B, Muniz-Feliciano L, Laskowski TJ, Liang S, Moyes JS, Nandivada V, Basar R, Kaplan M, Daher M, Liu E, Li Y, Acharya S, Lin P, Shanley M, Rafei H, Marin D, Mielke S, Champlin RE, Shpall EJ, Chen K, Rezvani K (2023). Loss of metabolic fitness drives tumor resistance after CAR-NK cell therapy and can be overcome by cytokine engineering. Sci Adv, 9(30), eadd6997.
  10. Waldschmidt JM, Yee AJ, Vijaykumar T, Pinto RA, Frede J, Anand P, Bianchi G, Guo G, Potdar S, Seifer C, Nair MS, Kokkalis A, Kloeber JA, Shapiro S, Budano L, Mann M, Friedman R, Lipe B, Campagnaro E, O'Donnell EK, Zhang CZ, Laubach JP, Munshi NC, Richardson PG, Anderson KC, Raje NS, Knoechel B, Lohr JG (2022). Cell-free DNA for the detection of emerging treatment failure in relapsed/ refractory multiple myeloma. Leukemia, 36(4), 1078-1087.
  11. Fishman H, Madiwale S, Geron I, Bari V, Van Loocke W, Kirschenbaum Y, Ganmore I, Kugler E, Rein-Gil A, Friedlander G, Schiby G, Birger Y, Strehl S, Soulier J, Knoechel B, Ferrando A, Noy-Lotan S, Nagler A, Mulloy JC, Van Vlierberghe P, Izraeli S (2022). ETV6-NCOA2 fusion induces T/myeloid mixed-phenotype leukemia through transformation of nonthymic hematopoietic progenitor cells. Blood, 139(3), 399-412.
  12. Montanaro A, Kitara S, Cerretani E, Marchesini M, Rompietti C, Pagliaro L, Gherli A, Su A, Minchillo ML, Caputi M, Fioretzaki R, Lorusso B, Ross L, Alexe G, Masselli E, Marozzi M, Rizzi FMA, La Starza R, Mecucci C, Xiong Y, Jin J, Falco A, Knoechel B, Aversa F, Candini O, Quaini F, Sportoletti P, Stegmaier K, Roti G (2022). Identification of an Epi-metabolic dependency on EHMT2/G9a in T-cell acute lymphoblastic leukemia. Cell Death Dis, 13(6), 551.
  13. Im NG, Guillaumet-Adkins A, Wal M, Rogers AJ, Frede J, Havig CC, Yang J, Anand P, Stegmann SK, Waldschmidt JM, Sotudeh N, Niu L, Voisine J, Schweiger MR, Grassberger C, Lohr JG, Knoechel B (2022). Regulatory Programs of B-cell Activation and Germinal Center Reaction Allow B-ALL Escape from CD19 CAR T-cell Therapy. Cancer Immunol Res, 10(9), 1055-1068.
  14. Anand P, Guillaumet-Adkins A, Dimitrova V, Yun H, Drier Y, Sotudeh N, Rogers A, Ouseph MM, Nair M, Potdar S, Isenhart R, Kloeber JA, Vijaykumar T, Niu L, Vincent T, Guo G, Frede J, Harris MH, Place AE, Silverman LB, Teachey DT, Lane AA, DeAngelo DJ, Aster JC, Bernstein BE, Lohr JG, Knoechel B (2021). Single-cell RNA-seq reveals developmental plasticity with coexisting oncogenic states and immune evasion programs in ETP-ALL. Blood, 137(18), 2463-2480.
  15. Frede J, Anand P, Sotudeh N, Pinto RA, Nair MS, Stuart H, Yee AJ, Vijaykumar T, Waldschmidt JM, Potdar S, Kloeber JA, Kokkalis A, Dimitrova V, Mann M, Laubach JP, Richardson PG, Anderson KC, Raje NS, Knoechel B, Lohr JG (2021). Dynamic transcriptional reprogramming leads to immunotherapeutic vulnerabilities in myeloma. Nat Cell Biol, 23(11), 1199-1211.
  16. Waldschmidt JM, Kloeber JA, Anand P, Frede J, Kokkalis A, Dimitrova V, Potdar S, Nair MS, Vijaykumar T, Im NG, Guillaumet-Adkins A, Chopra N, Stuart H, Budano L, Sotudeh N, Guo G, Grassberger C, Yee AJ, Laubach JP, Richardson PG, Anderson KC, Raje NS, Knoechel B, Lohr JG (2021). Single-Cell Profiling Reveals Metabolic Reprogramming as a Resistance Mechanism in BRAF-Mutated Multiple Myeloma. Clin Cancer Res, 27(23), 6432-6444.
  17. Ramaswamy K, Forbes L, Minuesa G, Gindin T, Brown F, Kharas MG, Krivtsov AV, Armstrong SA, Still E, de Stanchina E, Knoechel B, Koche R, Kentsis A (2018). Peptidomimetic blockade of MYB in acute myeloid leukemia. Nat Commun, 9(1), 110.
  18. Guo G, Raje NS, Seifer C, Kloeber J, Isenhart R, Ha G, Yee AJ, O'Donnell EK, Tai YT, Richardson PG, Bianchi G, Laubach JP, Warren D, Gemme E, Voisine J, Frede J, Kokkalis A, Yun H, Dimitrova V, Vijaykumar T, Meyerson M, Munshi NC, Anderson KC, Knoechel B, Lohr JG (2018). Genomic discovery and clonal tracking in multiple myeloma by cell-free DNA sequencing. Leukemia, 32(8), 1838-1841.
  19. Mandelbaum J, Shestopalov IA, Henderson RE, Chau NG, Knoechel B, Wick MJ, Zon LI (2018). Zebrafish blastomere screen identifies retinoic acid suppression of MYB in adenoid cystic carcinoma. J Exp Med, 215(10), 2673-2685.
  20. Ariës IM, Bodaar K, Karim SA, Chonghaile TN, Hinze L, Burns MA, Pfirrmann M, Degar J, Landrigan JT, Balbach S, Peirs S, Menten B, Isenhart R, Stevenson KE, Neuberg DS, Devidas M, Loh ML, Hunger SP, Teachey DT, Rabin KR, Winter SS, Dunsmore KP, Wood BL, Silverman LB, Sallan SE, Van Vlierberghe P, Orkin SH, Knoechel B, Letai AG, Gutierrez A (2018). PRC2 loss induces chemoresistance by repressing apoptosis in T cell acute lymphoblastic leukemia. J Exp Med, 215(12), 3094-3114.
  21. Drier Y, Cotton MJ, Williamson KE, Gillespie SM, Ryan RJ, Kluk MJ, Carey CD, Rodig SJ, Sholl LM, Afrogheh AH, Faquin WC, Queimado L, Qi J, Wick MJ, El-Naggar AK, Bradner JE, Moskaluk CA, Aster JC, Knoechel B, Bernstein BE (2016). An oncogenic MYB feedback loop drives alternate cell fates in adenoid cystic carcinoma. Nat Genet, 48(3), 265-72.
  22. Lohr JG, Kim S, Gould J, Knoechel B, Drier Y, Cotton MJ, Gray D, Birrer N, Wong B, Ha G, Zhang CZ, Guo G, Meyerson M, Yee AJ, Boehm JS, Raje N, Golub TR (2016). Genetic interrogation of circulating multiple myeloma cells at single-cell resolution. Sci Transl Med, 8(363), 363ra147.
  23. Knoechel B, Bhatt A, Pan L, Pedamallu CS, Severson E, Gutierrez A, Dorfman DM, Kuo FC, Kluk M, Kung AL, Zweidler-McKay P, Meyerson M, Blacklow SC, DeAngelo DJ, Aster JC (2015). Complete hematologic response of early T-cell progenitor acute lymphoblastic leukemia to the ¿-secretase inhibitor BMS-906024: genetic and epigenetic findings in an outlier case. Cold Spring Harb Mol Case Stud, 1(1), a000539.
  24. Knoechel B, Aster JC (2015). Metabolic Mechanisms of Drug Resistance in Leukemia. Cell Metab, 22(5), 759-60.
  25. Lohr JG, Stojanov P, Carter SL, Cruz-Gordillo P, Lawrence MS, Auclair D, Sougnez C, Knoechel B, Gould J, Saksena G, Cibulskis K, McKenna A, Chapman MA, Straussman R, Levy J, Perkins LM, Keats JJ, Schumacher SE, Rosenberg M, Multiple Myeloma Research Consortium, Getz G, Golub TR (2014). Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy. Cancer Cell, 25(1), 91-101.
  26. Knoechel B, Roderick JE, Williamson KE, Zhu J, Lohr JG, Cotton MJ, Gillespie SM, Fernandez D, Ku M, Wang H, Piccioni F, Silver SJ, Jain M, Pearson D, Kluk MJ, Ott CJ, Shultz LD, Brehm MA, Greiner DL, Gutierrez A, Stegmaier K, Kung AL, Root DE, Bradner JE, Aster JC, Kelliher MA, Bernstein BE (2014). An epigenetic mechanism of resistance to targeted therapy in T cell acute lymphoblastic leukemia. Nat Genet, 46(4), 364-70.
  27. Stoeck A, Lejnine S, Truong A, Pan L, Wang H, Zang C, Yuan J, Ware C, MacLean J, Garrett-Engele PW, Kluk M, Laskey J, Haines BB, Moskaluk C, Zawel L, Fawell S, Gilliland G, Zhang T, Kremer BE, Knoechel B, Bernstein BE, Pear WS, Liu XS, Aster JC, Sathyanarayanan S (2014). Discovery of biomarkers predictive of GSI response in triple-negative breast cancer and adenoid cystic carcinoma. Cancer Discov, 4(10), 1154-67.
  28. Riggi N, Knoechel B, Gillespie SM, Rheinbay E, Boulay G, Suvà ML, Rossetti NE, Boonseng WE, Oksuz O, Cook EB, Formey A, Patel A, Gymrek M, Thapar V, Deshpande V, Ting DT, Hornicek FJ, Nielsen GP, Stamenkovic I, Aryee MJ, Bernstein BE, Rivera MN (2014). EWS-FLI1 utilizes divergent chromatin remodeling mechanisms to directly activate or repress enhancer elements in Ewing sarcoma. Cancer Cell, 26(5), 668-681.
  29. Yashiro-Ohtani Y, Wang H, Zang C, Arnett KL, Bailis W, Ho Y, Knoechel B, Lanauze C, Louis L, Forsyth KS, Chen S, Chung Y, Schug J, Blobel GA, Liebhaber SA, Bernstein BE, Blacklow SC, Liu XS, Aster JC, Pear WS (2014). Long-range enhancer activity determines Myc sensitivity to Notch inhibitors in T cell leukemia. Proc Natl Acad Sci U S A, 111(46), E4946-53.
  30. Kluk MJ, Ashworth T, Wang H, Knoechel B, Mason EF, Morgan EA, Dorfman D, Pinkus G, Weigert O, Hornick JL, Chirieac LR, Hirsch M, Oh DJ, South AP, Leigh IM, Pourreyron C, Cassidy AJ, Deangelo DJ, Weinstock DM, Krop IE, Dillon D, Brock JE, Lazar AJ, Peto M, Cho RJ, Stoeck A, Haines BB, Sathayanrayanan S, Rodig S, Aster JC (2013). Gauging NOTCH1 Activation in Cancer Using Immunohistochemistry. PLoS One, 8(6), e67306.
  31. Lohr JG, Stojanov P, Lawrence MS, Auclair D, Chapuy B, Sougnez C, Cruz-Gordillo P, Knoechel B, Asmann YW, Slager SL, Novak AJ, Dogan A, Ansell SM, Link BK, Zou L, Gould J, Saksena G, Stransky N, Rangel-Escareño C, Fernandez-Lopez JC, Hidalgo-Miranda A, Melendez-Zajgla J, Hernández-Lemus E, Schwarz-Cruz y Celis A, Imaz-Rosshandler I, Ojesina AI, Jung J, Pedamallu CS, Lander ES, Habermann TM, Cerhan JR, Shipp MA, Getz G, Golub TR (2012). Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing. Proc Natl Acad Sci U S A, 109(10), 3879-84.
  32. Barron L, Knoechel B, Lohr J, Abbas AK (2008). Cutting edge: contributions of apoptosis and anergy to systemic T cell tolerance. J Immunol, 180(5), 2762-6.
  33. Knoechel B, Lohr J, Zhu S, Wong L, Hu D, Ausubel L, Abbas AK (2006). Functional and molecular comparison of anergic and regulatory T lymphocytes. J Immunol, 176(11), 6473-83.
  34. Lohr J, Knoechel B, Wang JJ, Villarino AV, Abbas AK (2006). Role of IL-17 and regulatory T lymphocytes in a systemic autoimmune disease. J Exp Med, 203(13), 2785-91.
  35. Knoechel B, Lohr J, Kahn E, Abbas AK (2005). The link between lymphocyte deficiency and autoimmunity: roles of endogenous T and B lymphocytes in tolerance. J Immunol, 175(1), 21-6.
  36. Knoechel B, Lohr J, Kahn E, Bluestone JA, Abbas AK (2005). Sequential development of interleukin 2-dependent effector and regulatory T cells in response to endogenous systemic antigen. J Exp Med, 202(10), 1375-86.
  37. Dooms H, Kahn E, Knoechel B, Abbas AK (2004). IL-2 induces a competitive survival advantage in T lymphocytes. J Immunol, 172(10), 5973-9.
  38. Lohr J, Knoechel B, Kahn EC, Abbas AK (2004). Role of B7 in T cell tolerance. J Immunol, 173(8), 5028-35.
  39. Abbas AK, Lohr J, Knoechel B, Nagabhushanam V (2004). T cell tolerance and autoimmunity. Autoimmun Rev, 3(7-8), 471-5.
  40. Lohr J, Knoechel B, Jiang S, Sharpe AH, Abbas AK (2003). The inhibitory function of B7 costimulators in T cell responses to foreign and self-antigens. Nat Immunol, 4(7), 664-9.
  41. von Bernuth H, Knöchel B, Winkler U, Roesler J, Schlesier M, Gahr M (2002). Immunodeficiency with recurrent panlymphocytopenia, impaired maturation of B lymphocytes, impaired interaction of T and B lymphocytes, and impaired integrity of epithelial tissue: a variant of idiopathic CD4+ T lymphocytopenia? Pediatr Allergy Immunol, 13(5), 381-4.
  42. Julius P, Luttmann W, Knoechel B, Kroegel C, Matthys H, Virchow JC Jr (1999). CD69 surface expression on human lung eosinophils after segmental allergen provocation. Eur Respir J, 13(6), 1253-9.
  43. Luttmann W, Knoechel B, Foerster M, Matthys H, Virchow JC Jr, Kroegel C (1996). Activation of human eosinophils by IL-13. Induction of CD69 surface antigen, its relationship to messenger RNA expression, and promotion of cellular viability. J Immunol, 157(4), 1678-83.
  44. Knöchel B, Luttmann W, Kroegel C (1996). [Prevention of the development of immediate hypersensitivity and airway hyperresponsiveness following in vivo treatment with soluble IL-4 receptor]. Pneumologie, 50(8), 569-70.

Review

  1. Waldschmidt JM, Vijaykumar T, Knoechel B, Lohr JG (2020). Tracking myeloma tumor DNA in peripheral blood. [Review]. Best Pract Res Clin Haematol, 33, (1), 101146.
  2. Waldschmidt JM, Anand P, Knoechel B, Lohr JG (2018). Comprehensive characterization of circulating and bone marrow-derived multiple myeloma cells at minimal residual disease. [Review]. Semin Hematol, 55, (1), 33-37.
  3. Knoechel B, Lohr JG (2013). Genomics of lymphoid malignancies reveal major activation pathways in lymphocytes. [Review]. J Autoimmun, 45, 15-23.
  4. Lohr J, Knoechel B, Caretto D, Abbas AK (2009). Balance of Th1 and Th17 effector and peripheral regulatory T cells. [Review]. Microbes Infect, 11, (5), 589-93.
  5. Abbas AK, Lohr J, Knoechel B (2007). Balancing autoaggressive and protective T cell responses. [Review]. J Autoimmun, 28, (2-3), 59-61.
  6. Lohr J, Knoechel B, Abbas AK (2006). Regulatory T cells in the periphery. [Review]. Immunol Rev, 212, 149-62.
  7. Lohr J, Knoechel B, Nagabhushanam V, Abbas AK (2005). T-cell tolerance and autoimmunity to systemic and tissue-restricted self-antigens. [Review]. Immunol Rev, 204, 116-27.